{"commentary":{"count":5,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":3,"podcast":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"STARLIGHT-1","nct_id":"NCT06343311","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=starlight-1-nct06343311. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"STARLIGHT-1","arms":[{"description":"Experimental: Dose Escalation, RP2D Confirmatory, and Expansion (Phase 1/2 Single Arm)\n\nDose Escalation Cohort: Participants receive a single infusion of EB103 at one of two predefined dose levels on Day 0 (completed).\n\nRP2D Confirmatory Cohort: Participants receive EB103 at the RP2D on Day 0.\n\nExpansion Cohort: Participants receive an initial EB103 T-cell infusion at the RP2D on Day 0 followed by a second EB103 T-cell infusion administered according to the protocol-defined schedule.","label":"EB103","type":"EXPERIMENTAL"}],"collaborators":["Eureka Therapeutics Inc."],"completion_date":{"date":"2028-07-31","type":"ESTIMATED"},"conditions":["B-Cell Non-Hodgkin's Lymphoma (NHL)","Lymphoma, Non-Hodgkins","Lymphomas Non-Hodgkin's B-Cell","Non-Hodgkin Lymphoma","Non-Hodgkin's Lymphoma","Large B-Cell Lymphoma","Lymphoma, Non-Hodgkin's, Adult","Lymphoma","Refractory Non-Hodgkin Lymphoma","Relapsed Non-Hodgkin Lymphoma","Lymphoma, Non-Hodgkin","HIV Associated Lymphoma","CNS Lymphoma","High-grade B-cell Lymphoma","Refractory B-Cell Non-Hodgkin Lymphoma"],"enrollment":{"count":27,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"EB103","type":"BIOLOGICAL"}],"last_update":"2026-10-01","lead_sponsor":"Estrella Immunopharma, Inc.","official_title":"An Open-Label, Dose Escalation, Multi-Center Phase I/II Clinical Trial of EB103 T-Cell Therapy in Adults With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2027-07-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"To assess the safety and tolerability of EB103.","timeFrame":"Up to 2 years (active assessment period); additional long-term follow-up (LTFU) up to 15 years"},{"measure":"To determine the Recommended Phase II Dose (RP2D) of EB103 (in Phase 1, Dose Escalation)","timeFrame":"Time Frame: 16 months"}],"references":[],"start_date":{"date":"2024-06-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)","url":"https://clinicaltrials.gov/study/NCT06343311"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/starlight-1-nct06343311"}